RenovoRx, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated revenues of $563,000, marking a 186% increase from $197,000 in the same period last year. This growth is attributed to the acceleration of the commercial rollout of its RenovoCath device, which has seen increased utilization across its expanding network of active cancer centers. The company noted that this revenue represents more than 50% of its total revenue for the entire year of 2025, indicating a strong upward trajectory in sales.
In terms of expenses, RenovoRx reported a total operating expense of $3.9 million for the first quarter of 2026, up from $3.2 million in the prior year, reflecting a 23% increase. The rise in expenses was primarily driven by a significant increase in selling, general, and administrative costs, which rose to $2.7 million from $1.6 million. Research and development expenses decreased to $1.2 million from $1.6 million, reflecting a strategic shift in resource allocation as the company focuses on commercial activities. Despite the increase in revenue, RenovoRx reported a net loss of $3.5 million for the quarter, compared to a net loss of $2.4 million in the same period last year.
Operationally, RenovoRx has expanded its active commercial cancer centers from 5 at the beginning of 2025 to 16 as of May 2026, with an additional 32 centers in various stages of evaluation and onboarding. This expansion is expected to significantly enhance the company’s market presence and revenue potential. The company anticipates that up to 15 clinical trial sites from its ongoing Phase III TIGeR-PaC trial will transition to commercial use, further contributing to revenue growth in the latter half of 2026.
Looking ahead, RenovoRx maintains a positive outlook, estimating a total addressable market of approximately $400 million for the RenovoCath device, with potential for several billion dollars as the platform expands into additional solid tumor indications. The company is also advancing its drug-device combination product candidate, intra-arterial gemcitabine (IAG), which is currently under investigation in the TIGeR-PaC trial. RenovoRx expects to complete enrollment for this trial by the end of June 2026, with final data anticipated in mid to late 2027.
As of March 31, 2026, RenovoRx had cash and cash equivalents of approximately $12.4 million, following a successful private placement that raised $10 million. The company has incurred significant losses since its inception and does not expect to achieve positive cash flows in the near future. However, it believes its current cash resources will be sufficient to fund operations for at least the next 12 months, while also indicating the potential need for additional capital to support ongoing commercialization and development efforts.
About RenovoRx, Inc.
RenovoRx, Inc. is a life sciences company specializing in targeted drug delivery for difficult-to-treat cancers. Its core product, RenovoCath, is an FDA-cleared device utilizing the proprietary TAMP platform to precisely deliver chemotherapy directly to tumors, minimizing systemic toxicity. The company develops innovative drug-device combinations, with a focus on pancreatic and other solid tumors, serving oncology and interventional radiology markets through clinical trials and commercialization efforts.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.